



Q4 & Full Year 2022 Financial and Business Update

February 21, 2023



Forward Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 21, 2023 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Our Three-Pillar Growth Strategy



Optimize WAKIX®
Performance



Expand Clinical Utility of
Pitolisant




Acquire
New Assets

DESIGNED TO SUPPORT LONG TERM SUSTAINABLE GROWTH


WAKIX® Net Revenue Performance

CONFIDENT IN WAKIX BECOMING A POTENTIAL >\$1B+ FRANCHISE VIA NARCOLEPSY AND ADDITIONAL INDICATIONS

WAKIX QUARTERLY NET REVENUE (\$M)



WAKIX ANNUAL NET REVENUE (\$M)



Driving Growth Through Strong Commercialization of WAKIX®

Q4 2022 Performance





Development Pipeline

Product / Indication	Pre-IND	Phase 1	Phase 2	Phase 3	Regulatory Filing ¹	Marketed Product	Milestone
WAKIX®							
EDS in Narcolepsy (Adults)							
Cataplexy in Narcolepsy (Adults)							
Pitolisant							
Pediatric Narcolepsy ²							Positive CHMP Opinion 1Q2023
Idiopathic Hypersomnia (IH)							Trial initiated 2Q2022
Prader-Willi Syndrome (PWS)							Topline data 4Q2022
Myotonic Dystrophy (DM)							Topline data 4Q2023
New Pitolisant Assets							New Bioprojet Agreement Closed 3Q2022
HBS-102							
PWS							Preclinical POC study initiated 3Q2022



Financial Highlights

(In millions, USD)


Net Product Revenues



Non-GAAP Adjusted Net Income⁽¹⁾



Cash, Cash Equivalents & Investment Securities



(1) Non-GAAP Adjusted Net Income= GAAP Net Income excluding non-cash interest expense, depreciation, amortization, stock-based compensation, other non-operating items and tax effect of these items

Financial Summary

<i>(In millions, USD)</i>	Three Months Ended December 31,		% Change	Year Ended December 31,		% Change
	2022	2021		2022	2021	
<i>Totals may not foot due to rounding</i>						
Net Product Revenues	\$128.3	\$91.2	41%	\$437.9	\$305.4	43%
Cost of Product Sold	26.9	17.8	51%	83.5	55.5	50%
Total Operating Expenses	\$53.8	\$44.8	20%	\$234.2	\$162.4	44%
R&D Expense	10.1	7.5	35%	70.9	30.4	NM
S&M Expense	21.1	19.1	10%	79.3	68.1	16%
G&A Expense	22.6	18.2	24%	84.0	63.9	31%
Net Income	\$48.5	\$22.7	114%	\$181.5	\$34.6	NM
Cash, cash equivalents & investment securities				\$345.7	\$234.3	48%

NM denotes not meaningful % change

GAAP vs NON-GAAP Reconciliation

<i>(In millions, USD)</i>	Three Months Ended December 31,		Year Ended December 31,	
	2022	2021	2022	2021
Totals may not foot due to rounding				
GAAP net income	\$48.5	\$22.7	\$181.5	\$34.6
Non-cash interest expense ⁽¹⁾	0.4	0.4	1.7	2.2
Depreciation	0.1	0.1	0.4	0.4
Amortization ⁽²⁾	6.0	4.6	23.0	18.4
Stock-based compensation expense	7.7	4.4	26.9	16.1
Licensing fee ⁽³⁾	-	-	30.0	-
Loss on debt extinguishment	-	-	-	26.1
Valuation allowance release	-	-	(74.5)	-
Income tax effect related to Non-GAAP adjustments ⁽⁴⁾	(0.7)	(1.8)	(5.4)	(6.3)
Non-GAAP adjusted net income	\$61.9	\$30.4	\$183.5	\$91.7
GAAP net income per diluted share	\$0.79	\$0.38	\$2.97	\$0.58
Non-GAAP adjusted net income per diluted share	\$1.01	\$0.50	\$3.00	\$1.55
Weighted average number of shares of common stock used in non-GAAP diluted per share	61,620,712	60,314,395	61,097,045	59,205,213

(1) Includes amortization of deferred finance charges

(2) Includes amortization of intangible asset related to WAKIX

(3) Amount represents initial licensing fee incurred upon closing the 2022 Licensing and Commercialization Agreement with Bioprojet

(4) Calculated using the reported effective tax rate for the periods presented less impact of valuation allowance release and discrete items

Harmony Continues To Be A Growth Story

Strong Commercial Performance & Future Growth of WAKIX in Narcolepsy



Poised to Extend Pitolisant Value Proposition Beyond Narcolepsy with IH, PWS & DM

New Development Programs to Expand Portfolio, Treatment Options



Talented Team & Solid Balance Sheet Positioned for Next Level of Growth





Thank You

